A Study to Evaluate the Efficacy and Safety of ALS-L1023 in Subjects With NASH

Inclusion Criteria: * Men or women ages 19 and over, under 75 years of age * Patients diagnosed with NAFLD on abdominal ultrasonography and MRI * Patients show presence of hepatic fat fraction as defined by ≥ 8% on MRI-PDFF and liver stiffness as defined by ≥ 2.5 kPa on MRE at Screening Exclusion Criteria: * Any subject with current, significant alcohol consumption or a history of significant alcohol consumption for a period of more than 3 consecutive months any time within 2 year prior to screening will be excluded * Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, viral hepatitis A, B, alcoholic liver disease * Uncontrolled diabetes mellitus as defined by a HbA1c ≥ 9.0％ at Screening * Patients who are allergic or hypersensitive to the drug or its constituents * Pregnant or lactating women